The Selection of Aptamers to CD20 and Their Application as Inhibitors of Complement Dependent Cytotoxicity
CD20 is an important oncological B-cell marker. Immunotherapy, using anti-CD20 antibodies, has revolutionized the treatment of B-cell cancers. Aptamers are highly specific DNA ligands, raised to identify virtually any target molecule through an iterative process known as SELEX (systematic evolution...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en |
| Published: |
Université d'Ottawa / University of Ottawa
2015
|
| Subjects: | |
| Online Access: | http://hdl.handle.net/10393/33182 http://dx.doi.org/10.20381/ruor-4060 |